The US Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for RP1 (vusolimogene ...

(RTTNews) - Replimune Group, Inc. (REPL), Tuesday announced that the U.S. Food and Drug Administration has accepted the Biologics License Application for RP1 in combination with Nivolumab for the ...

The biologics license application for RP1 (vusolimogene oderparepvec) plus nivolumab in advanced melanoma was accepted by the ...

Replimune Group Inc (NASDAQ: NASDAQ:REPL), a biotech firm focused on oncolytic immunotherapies, announced today that its Biologics License Application (BLA) for RP1 in combination with nivolumab has ...

Shares of Replimune Group, Inc. (NASDAQ: NASDAQ:REPL) surged 17% following the announcement that the U.S. Food and Drug ...

The addition of adjuvant nivolumab to standard-of-care radiotherapy and cisplatin improved survival for patients with locally ...

The confirmatory IGNYTE-3 trial is assessing RP1 in combination with nivolumab in patients with advanced melanoma who have progressed on anti-PD-1 and anti-CTLA-4 therapies or are ineligible for ...

HNSCC, whereas the combination of durvalumab and cetuximab showed limited success. Abenacianine received fast track designation for lung cancer surgery, the combination of amivantamab and Lazertinib ...

Oncology nurses can educate patients on the benefits of subcutaneous administration, including reduced time in the infusion ...

In the primary efficacy population, the median progression-free survival was not reached in the nivolumab-ipilimumab arm and was 5.9 months in the chemotherapy arm. The combination of nivolumab and ...

Choueiri, MD. The median progression-free survival was 5.7 months with nivolumab plus tivozanib and 7.4 months with tivozanib alone. Adding nivolumab to treatment with tivozanib does not improve ...

Dr. Eric K. Singhi discusses the benefit of subcutaneous immunotherapy following the FDA approval of subcutaneous Opdivo for ...